New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape
Authors:
Top Cited Papers
- 1 April 2014
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 27, 16-25
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcomaCancer Letters, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cellsNature Cell Biology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic MelanomaClinical Cancer Research, 2011
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer developmentNature, 2011
- Adaptive immunity maintains occult cancer in an equilibrium stateNature, 2007
- Interferons, immunity and cancer immunoeditingNature Reviews Immunology, 2006
- Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic MutationBMJ, 1957